Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with ...
Subcutaneous RYBREVANT®▼ (amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer ...
Dr Jérome Fayette, M.D., Ph.D., Principal Investigator of the study LYON, FRANCE, October 19, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage biotechnology company pioneering novel ...
SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025 ...
Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as ...
A massive Veterans Affairs study has confirmed that nicotinamide may offer real protection against skin cancer. Patients who ...
Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high local cure rates in the management of non-melanoma skin cancer.